Sep 26, 2022CSL Receives Manufacturing and Marketing Authorization in Japan for “Berinert® S.C. Injection 2000,” as a Medicine for prevention of Acute Hereditary Angioedema (HAE) attacks
CSL Behring K.K. (Head Office: Minato-ku, Tokyo; President and Representative Director: Jean-Marc Morange) announces that it has received a manufacturing and marketing approval from the Ministry of Health, Labour and Welfare for “Berinert® S.C. Injection 2000,” a lyophilized human C1-esterase inhibitor concentrate...
Sep 19, 2022
CSL applauds the United States District Court’s decision to issue a preliminary injunction preventing the United States Customs and Border Protection (CBP) from continuing to enforce its ban on plasma donations by Mexican nationals who enter the U.S. on a B-1/B-2 visa.
Sep 8, 2022Orphan Drug Designation granted for etranacogene dezaparvovec, CSL’s gene therapy for haemophilia B, by the Therapeutics Goods Administration
TGA’s designation underscores CSL’s promise to develop and deliver a truly unique portfolio of patient-focused therapies for people with rare and serious medical conditions
Aug 17, 2022CSL Announces Positive Top-Line Phase 3 Results for Garadacimab as Preventive Treatment in Patients with Hereditary Angioedema (HAE)
KING OF PRUSSIA, PA CSL is on track to file for regulatory approvals next year and will present full data set at an upcoming scientific congress 17 Aug 2022 Global biotechnology leader CSL...
- Jun 24, 2022CSL continues to provide medicines to patients around the world.
CSL continues to provide medicines to patients around the world. 24 Jun 2022 Safeguarding our people, patients and donors remains our top priority. As the COVID-19 pandemic evolves, CSL continues...